LAPS-Insulin (HM12460A)
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 16, 2022
Preoperative oral carbohydrates in elderly patients undergoing free flap surgery for oral cancer: randomized controlled trial.
(PubMed, Int J Oral Maxillofac Surg)
- "Thirst (P = 0.001) and hunger (P = 0.003) differed significantly between the two groups prior to anaesthesia induction. The intake of oral carbohydrate 2 hours before surgery was both safe and effective for elderly patients with oral cancer undergoing free flap surgery and could relieve the physiological stress response."
Journal • Anesthesia • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor
April 23, 2021
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=21; Terminated; Sponsor: Hanmi Pharmaceutical Company Limited; Suspended ➔ Terminated; Sopnsor decision
Clinical • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 12, 2020
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=21; Suspended; Sponsor: Hanmi Pharmaceutical Company Limited; Trial completion date: Sep 2019 ➔ Sep 2020
Clinical • Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 06, 2017
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=48; Recruiting; Sponsor: Hanmi Pharmaceutical Company Limited
New P1 trial • Biosimilar • Diabetes • Metabolic Disorders
February 28, 2018
Molar Potency Study of HM12460A in Healthy Subjects
(clinicaltrials.gov)
- P1; N=38; Completed; Sponsor: Hanmi Pharmaceutical Company Limited; Recruiting ➔ Completed; Trial primary completion date: Feb 2019 ➔ Feb 2018
Trial completion • Trial primary completion date • Biosimilar
September 24, 2019
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=21; Suspended; Sponsor: Hanmi Pharmaceutical Company Limited; Terminated ➔ Suspended
Clinical • Trial suspension
September 04, 2019
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=21; Terminated; Sponsor: Hanmi Pharmaceutical Company Limited; N=48 ➔ 21; Recruiting ➔ Terminated; Trial primary completion date: Jun 2019 ➔ Jan 2019; Administrative reasons
Clinical • Enrollment change • Trial primary completion date • Trial termination
1 to 7
Of
7
Go to page
1